Transformation of low grade glioma and correlation with outcome: An NCCTG database analysis

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 253-259

  Jaeckle, K A ^a   Decker, P A ^b   Ballman, K V ^b   Flynn, P J ^c   Giannini, C ^b   Scheithauer, B W ^b   Jenkins, R B ^b   Buckner, J C ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Metro MN   (United States)

Author keywords

De differentiation; Glioblastoma; Low grade glioma; Survival

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; 2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; AMONAFIDE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLADRIBINE; DACARBAZINE; EFLORNITHINE; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINATE CALCIUM; GEFITINIB; IFOSFAMIDE; IMATINIB; INTERFERON; IRINOTECAN; MESNA; PROCARBAZINE; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; VINCRISTINE;

ASTROCYTOMA; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; DATA BASE; GLIOBLASTOMA; GLIOMA; HIGH GRADE GLIOMA; HUMAN; LOW GRADE GLIOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052752036     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0476-2     Document Type: Review

References (25)

1. W Wu KR Lamborn JC Buckner P Novotny SM Chang JR O'Fallon E Galanis KA Jaeckle MD Prados 2010 Joint NCCTG and NABTC prognostic factors analysis for high grade recurrent glioma Neuro Oncol 12 2 164 172 20150383 1:CAS:528:DC%2BC3cXotFKitbo%3D
2. H Ohgaki 2007 Kleihues: genetic pathways to primary and secondary glioblastoma Am J Path 170 1445 1453 17456751 10.2353/ajpath.2007.070011 1:CAS:528:DC%2BD2sXlvFCns74%3D (Pubitemid 47339290)
3. EJ Dropcho SJ Soong 1996 The prognositic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study Neurology 47 684 690 8797465 1:STN:280:DyaK28zptVCkuw%3D%3D (Pubitemid 26307298)
4. H Ohgaki P Dessen B Jourde, et al. 2004 Genetic pathways to glioblastoma: a population-based study Cancer Res 64 6892 6899 15466178 10.1158/0008-5472. CAN-04-1337 1:CAS:528:DC%2BD2cXotFalsrc%3D (Pubitemid 39330996)
5. H Ohgaki 2005 Kleihues: population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J Neuropathol Exp Neurol 64 479 489 15977639 1:CAS:528:DC%2BD2MXlvVSgsbg%3D (Pubitemid 40781150)
6. F Pignatti M van den Bent D Curran European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group, et al. 2002 Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 2076 2084 11956268 10.1200/JCO.2002.08.121 (Pubitemid 34408798)
7. EF Chang JS Smith SM Chang, et al. 2008 Preoperative prognosic classification system for hemispheric low-grade gliomas in adults J Neurosurg 109 817 824 18976070 10.3171/JNS/2008/109/11/0817
8. M Law S Oh G Johnson, et al. 2006 Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas Neurosurgery 58 1099 1107 16723889 10.1227/01.NEU.0000215944.81730.18
9. B Caseiras O Ciccarelli DR Altmann, et al. 2009 Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient Radiology 253 505 512 10.1148/radiol.2532081623
10. MC Kruer AM Kaplan MM Etzl Jr, et al. 2009 The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood J Neurooncol 95 239 245 19506815 10.1007/s11060-009- 9922-4
11. JS Smith A Perry TJ Borell, et al. 2000 Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas J Clin Oncol 18 636 645 10653879 1:STN:280: DC%2BD3c7itVyrsA%3D%3D (Pubitemid 30078545)
12. Q Huang QB Zhang J Dong, et al. 2008 Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the de novo tumor, and both can be maintained long-term in vitro BMC Cancer 8 304 18940013 10.1186/1471-2407-8-304
13. N Sanai MS Berger 2009 Operative techniques for gliomas and the value of extent of resection Neurotherapeutics 6 478 486 19560738 10.1016/j.nurt.2009.04. 005
14. EG Shaw B Berkey SW Coons, et al. 2008 Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial J Neurosurg 109 835 841 18976072 10.3171/JNS/2008/109/11/0835
15. EF Chang A Clark RL Jensen, et al. 2009 Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article J Neurosurg 111 203 210 19267536 10.3171/2009.2.JNS081101
16. Martinez R, Rohde V, Schackert G: Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2009; Jul 31 (epub ahead of print)
17. R Martinez F Setien C Voelter, et al. 2007 CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme Carcinogenesis 28 1264 1268 17272309 10.1093/carcin/bgm014 1:CAS:528:DC%2BD2sXnt1CmtLY%3D (Pubitemid 47062686)
18. EA Maher C Brennan PY Wen, et al. 2006 Marked genomic differences characterize de novo and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities Cancer Res 66 11502 11513 17114236 10.1158/0008-5472.CAN-06-2072 1:CAS:528:DC%2BD28Xht1KnsLrK (Pubitemid 46009984)
19. H Zheng H Ying H Yan AC Kimmelman, et al. 2008 p53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation Nature 455 1129 1133 18948956 10.1038/nature07443 1:CAS:528:DC%2BD1cXht1yju7rE
20. Y Ruano T Ribalta AR de Lope, et al. 2009 Worse outcome in de novo glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration Am J Clin Pathol 131 257 263 19141386 10.1309/AJCP64YBDVCTIRWV 1:CAS:528:DC%2BD1MXisFCgs7w%3D
21. D Xie YX Zeng HJ Wang, et al. 2006 Expression of cytoplasmic and nuclear survivin in de novo and secondary human glioblastoma Br J Cancer 94 108 114 16404364 10.1038/sj.bjc.6602904 1:CAS:528:DC%2BD28XisVGgsw%3D%3D (Pubitemid 43088549)
22. K Somasundaram SP Reddy K Vinnakota, et al. 2005 Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma Oncogene 24 7073 7083 16103883 10.1038/sj.onc.1208865 1:CAS:528: DC%2BD2MXhtFCru7%2FP (Pubitemid 41573636)
23. JF Mineo A Bordron M Baroncini, et al. 2007 Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma J Neurooncol 85 281 287 17571214 10.1007/s11060-007-9424-1 (Pubitemid 350142517)
24. S Nobusawa T Watanabe P Kleihues, et al. 2009 IDH1 mutations as a molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 6002 6007 19755387 10.1158/1078-0432.CCR-09-0715 1:CAS:528: DC%2BD1MXhtF2ltbbL
25. JS Smith EF Chang KR Lamborn, et al. 2008 Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas J Clin Oncol 26 1338 1345 18323558 10.1200/JCO.2007.13.9337